期刊文献+

基质金属蛋白酶9对系统性红斑狼疮预后的影响 被引量:5

Effects of Matrix Metalloproteinase-9 in Patients with Systemic Lupus Erythematosus
下载PDF
导出
摘要 目的探讨基质金属蛋白酶9(MMP-9)对系统性红斑狼疮(SLE)预后的指导意义。方法选取2008年3月至2011年5月重庆市急救医疗中心收治的SLE患者83例,按照狼疮活动计算标准评价患者疾病活动积分并进行分组:积分>2分纳入SLE活动组(62例),积分≤1分纳入SLE稳定组(21例),另外同期选择80例健康体检者作为正常对照组。比较3组受试者的MMP-9水平及SLE患者治疗前后的MMP-9水平。结果 3组受试者MMP-9水平比较差异有统计学意义(P<0.01),且SLE活动组和SLE稳定组MMP-9水平显著低于正常对照组(P<0.05)。治疗前SLE患者MMP-9水平为(78±16)g/L,治疗后为(79±17)g/L,差异无统计学意义(P>0.05)。SLE患者MMP-9与其24 h尿蛋白、系统性红斑狼疮疾病活动度评分、抗ds-DNA呈明显负相关(r=-0.517,-0.832,-0.439,均P<0.05),与C3、C4呈明显正相关(r=0.355,0.360,均P<0.05)。结论患者外周血MMP-9水平下降提示机体炎性组织和受损血管中MMP-9水平上升,预后较差。 Objective To explore the matrix metalloproteinase 9( MMP-9) guidance for systemic lupus erythematosus( SLE) prognosis. Methods A total of 83 patients with SLE treated in Chongqing Emergency Medical Center from Mar. 2008 to May 2011 were selected,the lupus activity was calculated in accordance with the criteria to evaluate disease activity to group the patients: scores 〉2 into active SLE group( 62cases),scores≤1 into stable SLE group( 21 cases),and another 80 healthy persons during the same period were chosen as normal control group. MMP-9 levels of the three groups and of SLE patients before and after treatment were compared. Results The MMP-9 level of 3 groups had statistically significant differences( P 0. 01),and the activities of active SLE group and stable SLE group were significantly lower than the normal control group( P〉0. 05). MMP-9 levels in patients with SLE before treatment was( 78 ± 16) g / L,after treatment was( 79 ± 17) g / L,the difference was not statistically significant( P〈0. 05). MMP-9 was significantly negatively correlated with 24 h urine protein,systemic lupus erythematosus disease activity score,antids-DNA( r =- 0. 517,- 0. 832,- 0. 439,all P〈0. 05),and was significantly positively correlated with C3,C4( r = 0. 355,0. 360,all P〈0. 05). Conclusion MMP-9 levels in SLE patients is decreased,suggesting that MMP-9 content increases in the inflammatory tissue and damaged blood vessels,and the prognosis is poor.
作者 刘小玲
出处 《医学综述》 2016年第1期203-205,共3页 Medical Recapitulate
关键词 系统性红斑狼疮 基质金属蛋白酶9 明胶酶B 预后 Systemic lupus erythematosus Matrix metalloproteinase-9 Gelatinase B Prognosis
  • 相关文献

参考文献9

  • 1vinh quo'c Luong K,Nguyê'n LT.The beneficial role of vitamin D in systemic lupus erythematosus(SLE)[J].Clin Rheumatol,2012,31(10):1423-1435.
  • 2Efthimiou P,Blanco M.Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers[J].Mod Rheumatol,2009,19(5):457-468.
  • 3谢立虎,陈战瑞.基质金属蛋白酶-9及其与系统性红斑狼疮的关系[J].广东医学,2012,33(3):416-418. 被引量:1
  • 4Hsu TC,Chen YC,Lai WX,et al.Beneficial effects of treatment with cystamine on brain in NZB/W F1 mice[J].Eur J Pharmacol,2008,591(1/3):307-314.
  • 5Hwang BM,Noh EM,Kim JS,et al.Curcumin inhibits UVB-induced matrix metalloproteinase-1/3 expression by suppressing the MAPKp38/JNK pathways in human dermal fibroblasts[J].Exp Dermatol,2013,22(5):371-374.
  • 6刘梦琼,林永前,王俏梅,古升.类风湿关节炎和系统性红斑狼疮患者血清基质金属蛋白酶2、9检测的意义[J].检验医学,2009,24(12):883-885. 被引量:9
  • 7Ono Y,Torii K,Fritsche E,et al.Role of the aryl hydrocarbon receptor in tobacco smoke extract-induced matrix metalloproteinase-1 expression[J].Exp Dermatol,2013,22(5):349-353.
  • 8Park M,Han J,Lee CS,et al.Carnosic acid,a phenolic diterpene from rosemary,prevents UV-induced expression of matrix metalloproteinases in human skin fibroblasts and keratinocytes[J].Exp Dermatol,2013,22(5):336-341.
  • 9胡亮,彭奕冰,王学锋,巩惠芸.系统性红斑狼疮患者外周血MMP-2、MMP-3、MMP-9和TIMP-4水平的检测及其临床意义[J].诊断学理论与实践,2012,11(4):397-400. 被引量:2

二级参考文献39

  • 1边红,焉传祝,刘淑萍,吴金玲,李大年.基质金属蛋白酶在多发性肌炎/皮肌炎免疫发病机制中的作用研究[J].中国神经免疫学和神经病学杂志,2006,13(3):193-193. 被引量:2
  • 2Mannello F, Tonti GA, Bagnara GP, et al. Role and function of matrix metalloproteinases in the differentiation and biological characterization of mesenchymal stem cells [ J ]. Stem Cells, 2006, 24 (3) :475-481.
  • 3Chang YC, Yang SF, Tai KW, et al. Increased tissue inhibitor of metalloproteinase-1 expression and inhibition of gelatinase A activity in buccal mucosal fibroblasts by arecoline as possible mechanisms for oral submucous fibrosis [ J ]. Oral Oncol, 2002,38 ( 2 ) : 195-200.
  • 4Ainiala H, Hietaharju A, Dastidar P, et al. Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsyehiatrie manifestations and brain magnetic resonance imaging abnormalities [ J ]. Arthritis Rheum, 2004,50 ( 3 ) : 858- 865.
  • 5Iwaki-Egawa S,Watanabe Y, Matsuno H. Correlations between matrix metalloproteinase-9 and adenosine deaminase isozymes in synovial fluid from patients with rheumatoid arthritis[ J ]. J Rheumatol, 2001,28 ( 3 ) : 485-489.
  • 6Ahrens D, Koch AE, Pope RM, et al. Expression of matrix metalloproteinase 9 ( 96-kd gelatinase B ) in hmnan rheumatoid arthritis [ J ]. Arthritis Rheum, 1996,39 (9) : 1576-1587.
  • 7Makowski GS, Ranrsby ML. Concentrations of circulating matrix metalloproteinase 9 inversely correlate with autoimmune antibodies to double stranded DNA: implications for monitoring disease activity in systemic lupus erythematosus [ J ]. Mol Pathol, 2003,56 (4) : 244 -247.
  • 8Derosa G, Avanzini MA, Geroldi D, et al. Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus [ J ]. Diabetes Res Clin Praet, 2005,70 ( 2 ) : 119-125.
  • 9Kleiner ED,Stetler-Stevenson WG. Quantitative zymography: detection of picogram quantities of gelatinases [J]. Anal Siochem, 1994,218(2):325-329.
  • 10DUMONT O,LOUFRANI L,HENRION D.Key role of the NO-pathway and matrix metalloprotease-9 in high blood flow-in-duced remodeling of rat resistance arteries[J].ArteriosclerThromb Vasc Biol,2007,27(2):317-324.

共引文献9

同被引文献47

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部